
Tomoko Tadokoro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2382704/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers, 2021, 13, 514.	3.7	63
2	Diabetes mellitus and metformin in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 6100.	3.3	61
3	Cancer Therapy Due to Apoptosis: Galectin-9. International Journal of Molecular Sciences, 2017, 18, 74.	4.1	58
4	Albumin–bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatology Research, 2019, 49, 731-742.	3.4	40
5	Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. International Journal of Oncology, 2017, 51, 1674-1684.	3.3	39
6	Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. Oncology Reports, 2017, 38, 2825-2835.	2.6	39
7	Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. International Journal of Molecular Sciences, 2021, 22, 8139.	4.1	38
8	The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 8536-8549.	1.8	33
9	Galectin-9: An anticancer molecule for gallbladder carcinoma. International Journal of Oncology, 2016, 48, 1165-1174.	3.3	29
10	Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. Oncology Reports, 2016, 35, 851-860.	2.6	26
11	Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. American Journal of Physiology - Renal Physiology, 2020, 318, G401-G409.	3.4	26
12	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct‑acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncology Letters, 2020, 19, 2205-2212.	1.8	26
13	Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. Oncology Reports, 2017, 38, 506-514.	2.6	25
14	Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model. International Journal of Molecular Sciences, 2019, 20, 2634.	4.1	24
15	Correlation between serum galectinâ€9 levels and liver fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 492-499.	2.8	22
16	Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. International Journal of Oncology, 2015, 47, 1293-1302.	3.3	20
17	Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs. International Journal of Molecular Medicine, 2016, 38, 1135-1140.	4.0	18
18	Serum microRNA‑125a‑5p as a potential biomarker of HCV‑associated hepatocellular carcinoma. Oncology Letters, 2019, 18, 882-890.	1.8	18

Τομοκο Ταδοκογο

#	Article	IF	CITATIONS
19	Aspirin inhibits hepatocellular carcinoma cell proliferation inÂvitro and inÂvivo via inducing cell cycle arrest and apoptosis. Oncology Reports, 2020, 44, 457-468.	2.6	17
20	Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection. Journal of Clinical Medicine, 2018, 7, 267.	2.4	16
21	Galectin‑9 suppresses the tumor growth of colon cancer <i>inÂvitro</i> and <i>inÂvivo</i> . Oncology Reports, 2021, 45, .	2.6	15
22	MicroRNA Interference in Hepatic Host-Pathogen Interactions. International Journal of Molecular Sciences, 2021, 22, 3554.	4.1	14
23	Galectin-9 ameliorates fulminant liver injury. Molecular Medicine Reports, 2017, 16, 36-42.	2.4	12
24	Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study. International Journal of Oncology, 2017, 51, 607-614.	3.3	11
25	Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. Oncology Letters, 2020, 20, 1727-1733.	1.8	10
26	Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. International Journal of Molecular Sciences, 2018, 19, 1940.	4.1	9
27	Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir. Oncotarget, 2018, 9, 32054-32062.	1.8	8
28	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case–control study. Journal of Gastroenterology, 2022, 57, 19-29.	5.1	8
29	Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma. International Journal of Oncology, 2017, 50, 2145-2153.	3.3	7
30	Targeted sequencing of cancer‑associated genes in hepatocellular carcinoma using next‑generation sequencing. Oncology Letters, 2018, 15, 528-532.	1.8	6
31	Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48Âweeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg. Internal and Emergency Medicine, 2021, 16, 1559-1565.	2.0	6
32	Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells inÂvitro. Molecular Medicine Reports, 2020, 22, 1063-1071.	2.4	6
33	Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three†dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. Molecular and Clinical Oncology, 2019, 11, 447-454.	1.0	5
34	Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. Internal Medicine, 2018, 57, 1101-1104.	0.7	4
35	L-carnitine reduces hospital admissions in patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2021, 32, 288-293.	1.6	4
36	Association between microRNA‑527 and glypican‑3 in hepatocellular carcinoma. Oncology Letters, 2021, 21, 229.	1.8	3

#	Article	IF	CITATIONS
37	Multimodal treatment involving molecular targeted agents and on‑demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report. Molecular and Clinical Oncology, 2021, 15, 154.	1.0	3
38	Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. Cancers, 2021, 13, 4605.	3.7	3
39	Evaluation of in vivo efficacy of radiofrequency ablation with D-sorbitol in animal liver. Molecular and Clinical Oncology, 2016, 4, 183-186.	1.0	2
40	A case report of granulocyte colony-stimulating factor-producing hepatocellular carcinoma that recurred after long-term complete response. Clinical Journal of Gastroenterology, 2021, 14, 204-211.	0.8	2
41	Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. Internal and Emergency Medicine, 2021, 16, 2155-2162.	2.0	2
42	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. International Journal of Molecular Sciences, 2022, 23, 1667.	4.1	2
43	Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. Anticancer Research, 2022, 42, 1263-1275.	1.1	2
44	Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report. Experimental and Therapeutic Medicine, 2018, 16, 1026-1028.	1.8	1
45	Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by directâ€acting antiviral therapies. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1126-1135.	2.8	1
46	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers, 2021, 13, 2257.	3.7	1
47	Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up. Internal Medicine, 2021, 60, 1835-1838.	0.7	1
48	Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFNα-2a treatment after surgery for hepatocellular carcinoma: a case report. Acta Hepatologica Japonica, 2016, 57, 666-673.	0.1	0
49	A case of hepatocellular carcinoma with sarcomatous change without anticancer therapies showing recurrence in the skin of the right temporal region. Acta Hepatologica Japonica, 2017, 58, 233-240.	0.1	0
50	Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases. Acta Hepatologica Japonica, 2022, 63, 107-119.	0.1	0